Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
KOREA E & EX

Vascular Closure Device Preserves the Femoral Artery

By HospiMedica International staff writers
Posted on 28 Feb 2013
Print article
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
An innovative extravascular device facilitates entry site closure in patients undergoing percutaneous procedures through the femoral artery.

The Vascade Vascular Closure System (VCS) utilizes a unique delivery system based on a proprietary collapsible disc technology made of a biconvex low-profile nitinol, which provides temporary hemostasis during the procedure, eliminating the need for an intravascular component. Secure and rapid hemostasis is achieved by the deployment of a thrombogenic, resorbable collagen hemostatic coating patch, which accelerates coagulation at the arteriotomy site in the femoral artery by expanding approximately 13 times in volume, thus ensuring that the residual tissue tract is sufficiently filled and provides mechanical hemostasis.

The VCS is indicated for femoral arterial access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a procedural sheath. The simple-to-use technique avoids the need for sheath exchange or added complexity, enabling deployment in as little as 30 seconds. The Vascade VCS is a product of Cardiva Medical (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Vascade is a new generation of extravascular closure technology that offers significant advantages over conventional closure devices and manual compression,” said Frank Zidar, MD, of the Heart Hospital of Austin (TX, USA). “I am excited to be able to provide Vascade to my patients and to integrate it into my practice.”

The safety and effectiveness of Vascade VCS was evaluated in 420 patients across 21 clinical sites (up to 30 days post diagnostic or interventional procedures), that showed that the system is more effective than manual compression for mean time for hemostasis (TTH) and mean time to ambulation (TTA), and with fewer complications.

Related Links:

Cardiva Medical



Print article
LevMed LTD.

Channels

Critical Care

view channel
Image: The OsteoCool RF Ablation System (Photo courtesy of Medtronic).

Cooled Ablation System Treats Painful Spine Metastases

A new ablation system uses water-cooled radiofrequency (RF) probes to reduce patient pain when ablating metastatic spinal tumors. The OsteoCool RF Ablation System is intended for palliative treatment... Read more

Women's Health

view channel
Image: The Eclipse vaginal insert in deflated (L) and Inflated (R) states (Phoyo courtesy of Pelvalon).

Vaginal Insert Offers Alternative Treatment for Fecal Incontinence

A novel vaginal insert for bowel control eliminates the need for surgery or an in-office procedure for the treatment of female fecal incontinence (FI). The second-generation Eclipse System is comprised... Read more

Health IT

view channel
Image: The Rigel 62353 Plus tester (Photo courtesy of Rigel Medical).

Advanced Safety Tester Analyzes Diverse Medical Devices

An upgraded dedicated tester meets international standards for in-service and post-repair safety testing of 24 V and 48 V DC medical electronic devices. The Rigel 62353 Plus tester offers a range of... Read more

Hospital News

view channel

Geneia Partners with Hospitals on Population Health Training

Geneia (Harrisburg, PA, USA) will provide population health management training to members of the Illinois Health and Hospital Association (IHA; Chicago, USA). Through its education arm, The Geneia Institute, skills-based population health management programs will be delivered to IHA's 209 hospital and nearly 50 health... Read more

Business

view channel

Global Call for Action Against Drug-Resistant Infections

More than 80 leading international bodies came together to call on governments and industry to work in parallel and take comprehensive action against drug-resistant infections, as proclaimed in a joint declaration released at the World Economic Forum (Cologny, Switzerland), held during January 2016 in Davos (Switzerland).... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.